The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia

Leuk Lymphoma. 2014 Dec;55(12):2935-7. doi: 10.3109/10428194.2014.905774. Epub 2014 May 6.

Authors

Ahmet Emre Eskazan¹, Tugrul Elverdi, Fevzi Firat Yalniz, Ayse Salihoglu, Muhlis Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Yildiz Aydin, Nukhet Tuzuner, Ugur Ozbek, Teoman Soysal

Affiliation

¹ Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University , Istanbul , Turkey.

PMID: 24650055
DOI: 10.3109/10428194.2014.905774

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Benzamides / administration & dosage
Benzamides / economics
Benzamides / therapeutic use*
Chemistry, Pharmaceutical
Cost-Benefit Analysis
Drug Substitution
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Piperazines / administration & dosage
Piperazines / economics
Piperazines / therapeutic use*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / economics
Protein Kinase Inhibitors / therapeutic use*
Pyrimidines / administration & dosage
Pyrimidines / economics
Pyrimidines / therapeutic use*

Substances

Antineoplastic Agents
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate